[1]
|
Lopes, N.M.D., Lens, H.H.M., da Silva Brito, W.A., Bianchi, J.K., Marinello, P.C., Cecchini, R., Armani, A. and Cec-chini, A.L. (2022) Role of Papillary Thyroid Carcinoma Patients with Hashimoto Thyroiditis: Evaluation of Oxidative Stress and Inflammatory Markers. Clinical & Translational Oncology, 24, 2366-2378.
https://doi.org/10.1007/s12094-022-02891-y
|
[2]
|
尹经霞, 崔龙, 蒲丹岚, 等. 2023年《甲状腺结节和分化型甲状腺癌诊治指南(第二版)》解读[J]. 现代医药卫生, 2023, 39(8): 1261-1266.
|
[3]
|
Kitahara, C.M. and Schneider, A.B. (2022) Epidemiology of Thyroid Cancer. Cancer Epidemiology, Biomarkers & Prevention, 31, 1284-1297. https://doi.org/10.1158/1055-9965.EPI-21-1440
|
[4]
|
董芬, 张彪, 单广良. 中国甲状腺癌的流行现状和影响因素[J]. 中国癌症杂志, 2016, 26(1): 47-52.
|
[5]
|
孙嘉伟, 许晓君, 蔡秋茂, 等. 中国甲状腺癌发病趋势分析[J]. 中国肿瘤, 2013, 22(9): 690-693.
|
[6]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[7]
|
Elsheikh, T.M., Asa, S.L., Chan, J.K., DeLellis, R.A., HefFess, C.S., LiVolsi, V.A. and Wenig, B.M. (2008) Interobserver and Intraobserver Variation among Experts in the Diagnosis of Thyroid Follicular Lesions with Borderline Nuclear Features of Papillary Carcinoma. American Journal of Clinical Pathology, 130, 736-744.
https://doi.org/10.1309/AJCPKP2QUVN4RCCP
|
[8]
|
徐其银, 程若川. Galectin-3、Cytokeratin-19与桥本甲状腺炎[J]. 中国当代医药, 2010, 17(6): 18-19.
|
[9]
|
Caviglia, G.P., Ciruolo, M., Olivero, A., Carucci, P., Rolle, E., Rosso, C., Abate, M.L., Risso, A., Ribaldone, D.G., Tandoi, F., Saracco, G.M., Bugianesi, E. and Gaia, S. (2020) Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers, 12, Article 2776. https://doi.org/10.3390/cancers12102776
|
[10]
|
左敏, 欧慧婷, 李剑, 等. 甲状腺乳头状癌与良性乳头状增生中p16、CD56蛋白表达特点及诊断价值[J]. 临床与实验病理学杂志, 2011, 27(11): 1214-1217.
|
[11]
|
Mokhtari, M., Eftekhari, M. and Tahririan, R. (2013) Absent CD56 Expression in Papillary Thyroid Carcinoma: A Finding of Po-tential Diagnostic Value in Problematic Cases of Thyroid Pathology. Journal of Research in Medical Sciences, 18, 1046-1050.
|
[12]
|
史国恩, 包万智, 李轶春, 等. 联合检测CK19、BRAF及FAK在甲状腺乳头状癌中的诊断价值[J]. 系统医学, 2019, 4(1): 4-6.
|
[13]
|
刘宏巨. CK19、CD56及galectin-3在甲状腺乳头状癌中的诊断价值[J]. 检验医学与临床, 2017, 14(5): 658-659, 662.
|
[14]
|
de Matos, P.S., Ferreira, A.P., de Oliveira Facuri, F., et al. (2015) Use-fulness of HBME-1 Cytokeratin 19 and Galectin-3 Immunostaining in the Diagnosis of Thyroid Malignancy. Histo-pathology, 47, 391-401.
https://doi.org/10.1111/j.1365-2559.2005.02221.x
|
[15]
|
Nasr, M.R., Mukhopadhyay, S., Zhang, S. and Katzenstein, A.L.A. (2016) Immunohistochemical Markers in Diagnosis of Papillary Thyroid Carcinoma: Utility of HBME1 Com-bined with CK19 Immunostaining. Modern Pathology, 19, 1631-1637. https://doi.org/10.1038/modpathol.3800705
|
[16]
|
Murphy, K.M., Chen, F. and Clark, D.P. (2018) Identification of Immunohistochemical Biomarkers for Papillary Thyroid Carcinoma Using Gene Expression Profiling. Human Patholo-gy, 39, 420-426.
https://doi.org/10.1016/j.humpath.2007.07.015
|
[17]
|
Abdou, A.G., Shabaan, M., Abdallha, R. and Nabil, N. (2019) Diagnostic Value of TROP-2 and CK19 Expression in Papillary Thyroid Carcinoma in Both Surgical and Cytological Specimens. Clinical Pathology, 12.
https://doi.org/10.1177/2632010X19863047
|
[18]
|
王新杰, 李清怀. CK19、34βE12、E-cadherin在甲状腺乳头状癌组织中的表达及临床病理学意义[J]. 承德医学院学报, 2007, 24(4): 411-413.
|
[19]
|
南润玲, 尚培中, 谷化平, 等. 半乳糖凝集素3、细胞角蛋白19及甲状腺过氧化物酶在甲状腺乳头状癌中的表达及意义[J]. 中华临床医师杂志(电子版), 2013(6): 2381-2384.
|
[20]
|
王士娜, 王星, 王翠芳. 甲状腺微小乳头状癌的临床病理特征及诊断标志物的应用[J]. 中国医科大学学报, 2014, 43(11): 1051-1053.
|
[21]
|
Handra-Luca, A. and Tissier, F. (2017) Nucleolar Cytokeratin 19 in Thyroid Carcinoma. Applied Immunohistochemistry & Molecular Morphology, 25, e37. https://doi.org/10.1097/PAI.0000000000000386
|
[22]
|
Ma, H., Xu, S., Yan, J., et al. (2014) The Value of Tumor Markers in the Diagnosis of Papillary Thyroid Carcinoma Alone and in Combination. Polish Journal of Pathology, 65, 202-209. https://doi.org/10.5114/pjp.2014.45782
|
[23]
|
Erdogan-Durmus, S., Ozcan, D., Yarikkaya, E., Kurt, A. and Arslan, A. (2016) CD56, HBME-1 and Cytokeratin 19 Expressions in Papillary Thyroid Carcinoma and Nodular Thy-roid Lesions. Journal of Research in Medical Sciences, 21, 49. https://doi.org/10.4103/1735-1995.183986
|
[24]
|
储德强. CK17与CK19在口腔鳞状细胞癌组织中的表达及意义[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2011.
|
[25]
|
Zhu, X., Sun, T., Lu, H., et al. (2010) Diagnostic Significance of CK19, RET, Galectin-3 and HBME-1 Ex-pression for Papillary Thyroid Carcinoma. Journal of Clinical Pathology, 63, 786-789. https://doi.org/10.1136/jcp.2010.076901
|
[26]
|
Cui, W., Sang, W., Zheng, S., et al. (2012) Usefulness of Cy-tokeratin-19. Galectin-3, and Hector Battiforamesothelial-1 in the Diagnosis of Benign and Malignant Thyroid Nodules. Clinical Laboratory, 58, 673-680.
|
[27]
|
沈雷, 曹慧敏, 李苑. 基于分子生物学的甲状腺癌诊疗进展[J]. 外科研究与新技术, 2015, 4(3): 196-200.
|
[28]
|
Dunđerović, D., Lipkovski, J.M., Boričic, I., et al. (2015) Defining the Value of CD56, CK19, Galectin 3 andHBME-1 in Diagnosis of Follicular Cell Derived Lesions of Thyroid with Systematic Review of Literature. Diagnostic Pathology, 10, Article No. 196. https://doi.org/10.1186/s13000-015-0428-4
|
[29]
|
Huang, L., Wang, X., Huang, X., et al. (2018) Diagnostic Signif-icance of CK19, Galectin-3, CD56, TPO and Ki67 Expression and BRAF Mutation in Papillary Thyroid Carcinoma. Oncology Letters, 15, 4269-4277.
https://doi.org/10.3892/ol.2018.7873
|
[30]
|
El Demellawy, D., Nasr, A.L., Babay, S., et al. (2009) Diagnostic Utility of CD56 Immunohistochemistry in Papillary Carcinoma of the Thyroid. Journal of Pathology Research and Practice, 205, 303-309.
https://doi.org/10.1016/j.prp.2008.11.011
|
[31]
|
董丽儒, 杨虎, 李双 等. ER、PR、CD56和BRAFV600E在甲状腺乳头状癌中的表达及临床意义[J]. 武警后勤学院学报(医学版), 2015, 8(8): 605-608.
|
[32]
|
吴光锋, 范瑞, 王博. 甲状腺乳头状癌中CK19 Galectin-3 CyclinD1和CD56的表达和意义[J]. 实用医技杂志, 2017, 24(10): 1135-1137. https://doi.org/10.19522/j.cnki.1671-5098.2017.10.045
|
[33]
|
李学文, 张静谊. 不同亚型甲状腺微小乳头状癌组织中Ki-67、CK19、HBME-1、CD56的表达变化及机制分析[J]. 中国现代普通外科进展, 2023, 26(4): 310-312, 315.
|
[34]
|
Ahmed, H.G., El Hag, A.B.M., et al. (2023) Patterns of Thyroid Tumors in Northern Saudi Arabia with a Specific Focus on CK19, CD56, and Galectin-3 Tumor Markers. European Review for Medical and Pharmacological Sciences, 27, 5654-5661.
|
[35]
|
Abdel-Aziz, A. and Abdallah, D. (2019) Role of Immunohistochemistry in Diagnosis of Papillary Thyroid Carcinoma: The Use of Ck19, CD56, P63 and CD117. Journal of Cancer and Tumor International, 9, 1-11.
|